Jade Biosciences Inc (JBIO)

$16.53 +0.18 (1.10%)
Market Cap 752.17M
Revenue (ttm) 0.00
Net Income (ttm) -69.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 130,400
Avg Vol 289,044
Day's Range N/A - N/A
Shares Out 46.00M
Stochastic %K 62%
Beta 1.04
Analysts Strong Sell
Price Target $19.80

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences,...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 312 3013
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
OGUZATA
OGUZATA Dec. 20 at 11:18 PM
$JBIO It is a critical point, it must be followed carefully moment by moment.
0 · Reply
stayput
stayput Dec. 17 at 4:47 AM
$JBIO Up 32% after reverse split in April. I don’t fold . Avg $12.37. More money will be made imo. Takes some coins to hold imo. NFA
0 · Reply
Fred378
Fred378 Dec. 15 at 11:17 PM
$JBIO perking
0 · Reply
GoldenMickey
GoldenMickey Dec. 15 at 11:01 PM
$JBIO
0 · Reply
GoldenMickey
GoldenMickey Dec. 15 at 11:01 PM
$JBIO 17$
0 · Reply
JohnTrack
JohnTrack Dec. 15 at 12:10 PM
$JBIO offering https://www.rapidticker.com/news/jbio-jade-biosciences-announces-45-million-8a0452
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 9:04 PM
$JBIO Share Price: $13.49 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.98 – $4.87 Potential Upside: 77% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Dec. 5 at 3:09 PM
TD Cowen⬆️the PT on $VERA to $73 from $60 and reiterated at a Buy rating. $TVTX $OTSKY $JBIO $VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing, increasing our PT to $73 based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN.
0 · Reply
Quantumup
Quantumup Dec. 2 at 9:12 PM
Raymond James reiterated $VERA Strong Buy/$73 after pricing data for atacicept's competitor ( $OTSKY ) in the IgAN space, sibeprenlimab (Voyxact), was been disclosed. $OTSKY $TVTX $JBIO $VRTX ABBV ALNY IONS Here's what Raymond James had to say in its note: https://x.com/Quantumup1/status/1995963371083186594?s=20
0 · Reply
topstockalerts
topstockalerts Nov. 28 at 1:54 PM
Pre Market Top Gainers PT2 $MSS $VIXI $WAI $JBIO $GNSS
0 · Reply
Latest News on JBIO
Jade Biosciences Announces $45 Million Private Placement

Dec 15, 2025, 7:00 AM EST - 9 days ago

Jade Biosciences Announces $45 Million Private Placement

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:05 PM EST - 5 weeks ago

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Nov 8, 2025, 11:00 AM EST - 6 weeks ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Jade Biosciences to Participate in Upcoming Conferences

Nov 3, 2025, 7:00 AM EST - 7 weeks ago

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Oct 17, 2025, 4:05 PM EDT - 2 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Oct 7, 2025, 7:05 AM EDT - 2 months ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences Announces $135 Million Private Placement

Oct 7, 2025, 7:00 AM EDT - 2 months ago

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 6 months ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jul 1, 2025, 7:00 AM EDT - 6 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jun 9, 2025, 7:00 AM EDT - 7 months ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jun 2, 2025, 7:00 AM EDT - 7 months ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 8 months ago

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 8 months ago

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

OGUZATA
OGUZATA Dec. 20 at 11:18 PM
$JBIO It is a critical point, it must be followed carefully moment by moment.
0 · Reply
stayput
stayput Dec. 17 at 4:47 AM
$JBIO Up 32% after reverse split in April. I don’t fold . Avg $12.37. More money will be made imo. Takes some coins to hold imo. NFA
0 · Reply
Fred378
Fred378 Dec. 15 at 11:17 PM
$JBIO perking
0 · Reply
GoldenMickey
GoldenMickey Dec. 15 at 11:01 PM
$JBIO
0 · Reply
GoldenMickey
GoldenMickey Dec. 15 at 11:01 PM
$JBIO 17$
0 · Reply
JohnTrack
JohnTrack Dec. 15 at 12:10 PM
$JBIO offering https://www.rapidticker.com/news/jbio-jade-biosciences-announces-45-million-8a0452
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 9:04 PM
$JBIO Share Price: $13.49 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.98 – $4.87 Potential Upside: 77% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Dec. 5 at 3:09 PM
TD Cowen⬆️the PT on $VERA to $73 from $60 and reiterated at a Buy rating. $TVTX $OTSKY $JBIO $VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing, increasing our PT to $73 based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN.
0 · Reply
Quantumup
Quantumup Dec. 2 at 9:12 PM
Raymond James reiterated $VERA Strong Buy/$73 after pricing data for atacicept's competitor ( $OTSKY ) in the IgAN space, sibeprenlimab (Voyxact), was been disclosed. $OTSKY $TVTX $JBIO $VRTX ABBV ALNY IONS Here's what Raymond James had to say in its note: https://x.com/Quantumup1/status/1995963371083186594?s=20
0 · Reply
topstockalerts
topstockalerts Nov. 28 at 1:54 PM
Pre Market Top Gainers PT2 $MSS $VIXI $WAI $JBIO $GNSS
0 · Reply
Quantumup
Quantumup Nov. 26 at 12:22 PM
Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 12:28 PM
Clear Street has updated their rating for Jade Biosciences ( $JBIO ) to Buy with a price target of 25.
0 · Reply
Quantumup
Quantumup Nov. 25 at 11:57 AM
Clear Street🏁 $JBIO Buy/$25 $OTSKY $TVTX $NVS $VRTX IONS AZN CALT Clear Street said in its initiation report:
0 · Reply
CrispDry
CrispDry Nov. 21 at 7:04 PM
$JBIO what’s happening?
0 · Reply
Doozio
Doozio Nov. 21 at 5:30 PM
$JBIO Roger has a lot of room to run because it was always 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 18 at 2:13 PM
Guggenheim has adjusted their stance on Jade Biosciences ( $JBIO ), setting the rating to Buy with a target price of 14 → 17.
0 · Reply
StockScanners
StockScanners Nov. 18 at 6:47 AM
$JBIO reached 13.57
0 · Reply
topstockalerts
topstockalerts Nov. 17 at 7:39 PM
$JBIO buyers stepping in.. 🏦
0 · Reply
SwingTradesOnly
SwingTradesOnly Nov. 17 at 3:43 PM
$JBIO dat gap 👀
1 · Reply
StockScanners
StockScanners Nov. 15 at 4:14 AM
$JBIO keep watch if this holds above 10
0 · Reply
d_risk
d_risk Nov. 14 at 12:54 PM
$JBIO - Jade Biosciences, Inc. - 10Q - Updated Risk Factors JBIO’s risk factors now reflect its move to clinical stage, with heightened uncertainty around trial success, heavy reliance on JADE101, increased capital needs, global supply chain and enrollment challenges, expanded competition, shifting IP and regulatory risks, and new threats from cybersecurity, foreign expansion, and potential cash access issues. #Biotechnology #Cybersecurity #SupplyChain #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/JBIO/10-Q/2025-11-14
0 · Reply